REGENXBIO
REGENXBIO Logo
About REGENXBIO
REGENXBIO Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies for the treatment of retinal, metabolic, and neurodegenerative diseases. Its product candidates are based on the proprietary NAV Technology Platform, an adeno-associated virus gene delivery system. The company's pipeline includes therapies for wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, mucopolysaccharidosis types I and II, late-infantile neuronal ceroid lipofuscinosis type 2, and CLN2 disease. REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Founded in 2008, the company is headquartered in Rockville, Maryland.
Address
9804 Medical Center Drive,
Rockville, 20850
United States
Year founded
2008
Number of employees
300-400
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
